Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BGB 30813 (Primary) ; Tislelizumab (Primary)
  • Indications Carcinoma; Cervical cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Mesothelioma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Skin cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors BeOne Medicines

Most Recent Events

  • 22 May 2025 Status changed from recruiting to active, no longer recruiting.
  • 17 Dec 2024 The protocol has been amended to change in study time frame for its primary endpoint.
  • 17 Dec 2024 Planned End Date changed from 1 May 2026 to 1 Dec 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top